Navigation Links
PDL BioPharma Announces Second Quarter 2012 Financial Results
Date:8/2/2012

INCLINE VILLAGE, Nev., Aug. 2, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Royalty revenues for the second quarter of 2012 increased three percent to $125.9 million from $122.1 million reported in the second quarter of 2011. For the first six months of 2012, royalty revenues increased four percent to $203.2 million from $195.5 million reported in the comparable period of 2011. Total revenue for the first six months of 2012 of $203.2 million is one percent lower than total revenue for the first six months of 2011 of $205.5 million, as a result of a one-time settlement payment of $10 million from UCB Pharma received in 2011.

Royalty revenues for the second quarter of 2012 are based on first quarter 2012 product sales by PDL's licensees. The growth in royalty revenues was driven primarily by increased royalties from first quarter 2012 sales of Herceptin®, which is marketed by Genentech and Roche, Lucentis® and Xolair®, which are marketed by Genentech and Novartis, and Tysabri®, which is marketed by Elan and Biogen Idec. Royalty revenue for the second quarter is net of payments made under PDL's February 2011 settlement agreement with Novartis Pharma AG.

General and administrative expenses for the second quarter of 2012 were $5.1 million, compared with $3.8 million in the same quarter of 2011. For the six months ended June 30, 2012, general and administrative expenses were $12.1 million compared to $9.6 million in the comparable period of 2011. The increase in expenses for both the quarter and six months ended June 30, 2012, is primarily due to expense
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
2. Global Biopharmaceuticals Market 2011-2015
3. PDL BioPharma to Announce Second Quarter 2012 Financial Results on August 2, 2012
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
6. ePharmaSolutions To Acquire Global Patient Recruitment Firm Polaris BioPharma
7. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
8. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
9. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
10. Genesis Biopharma Mentioned Favorably in BioMedReports Article
11. Genesis Biopharma Issues Letter To Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Reports from CDC show ... from one or more chronic health conditions - including ... address some of these diseases, but may not eliminate ... face. While implanted nerve stimulation devices today offer relief, ... which can induce side effects. , To eliminate ...
(Date:12/19/2014)... Diego, CA (PRWEB) December 18, 2014 ... a limited time special on Sartorius Biohit products ... Free on mLINE pipettes, Picus Electronic Pipette Trade-in Program, ... by Health and Safety officers around the world. They ... manual pipetting. Other features include:, ,     Full ...
(Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
(Date:12/17/2014)... Achim Noack has been named global vice ... this position, Noack will assist Jerry Stoller, CEO and ... strategy and supervise global marketing management and implementation of ... knowledge and experience in the crop protection industry,” says ... innovative thinking will be a great asset for Stoller ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... Call on Thursday, November 5, 2009 at 4:30 p.m. ... /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") ... for the third quarter and nine months ended September ... third quarter of 2009. , The following consolidated results ...
... Wound Management Technologies, Inc., (WNDM), announced today that it has ... assets of Virtual Health Technologies, Inc. (OTC Bulletin Board: VHGI). ... cash and debt, 4,000,000 shares of WNDM and a royalty ... being acquired from VHGI. WNDM closed at $2.00 ...
... Nov. 5 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ) ... to release third quarter 2009 financial results on,Monday, November 9, ... The Company will hold a conference call at 5:00 pm ... Listeners may access the call by,dialing 1-888-713-4211 or 1-617-213-4864 ...
Cached Biology Technology:OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3BMP Sunstone to Report Third Quarter 2009 Financial Results 2
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... NEW YORK (January 14, 2008) Outbreaks of the notorious ... richest center of coral reef biodiversity on Earth, according to ... ARC Centre of Excellence for Coral Reef Studies. The ... its stomach over them and using digestive enzymes to liquefy ...
... Service Weekly PressPac with news from ACS 36 peer-reviewed journals ... the American Chemical Society as the source for this information. ... which is embargoed for 9 A. M., Eastern Time, Jan. ... Seagull blood shows promise for monitoring pollutants ...
... ARBOR, Mich.---An international study of 20,000 people found seven ... factor in heart disease, and confirmed 11 other genes ... international study led by researchers from the University of ... or confirm genetic variants that influence lipid levels, and ...
Cached Biology News:Starfish outbreak threatens corals 2American Chemical Society's weekly PressPac -- Jan. 9, 2008 2American Chemical Society's weekly PressPac -- Jan. 9, 2008 3American Chemical Society's weekly PressPac -- Jan. 9, 2008 4American Chemical Society's weekly PressPac -- Jan. 9, 2008 5American Chemical Society's weekly PressPac -- Jan. 9, 2008 6American Chemical Society's weekly PressPac -- Jan. 9, 2008 7American Chemical Society's weekly PressPac -- Jan. 9, 2008 8American Chemical Society's weekly PressPac -- Jan. 9, 2008 9Study locates cholesterol genes; finds surprises about good, bad cholesterol 2
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... Workstation for PCR set-up Easy ... to hold 0.2 ml PCR tubes, strips or Nunc ... handling systems Removable tray can be fitted ... V-bottom 0.2 ml tube block thermal cycler formats of ...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
...
Biology Products: